Avantel Ltd
AVANTELAvantel Ltd's price has outrun its earnings. +26.7% in a year against EPS −73.7% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +26.7% in a year while annual EPS moved −73.7% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (10 weeks in) while the P/E sits at the 93rd percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +66.9% year on year, and 101% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Avantel Ltd trades at ₹162, in a confirmed uptrend and 10 weeks into that stage. That is +2.1% against its own 200-day average. It sits at 47% of a 52-week range of ₹124 to ₹204. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (2 weeks and counting).
Today the stock is in a confirmed uptrend — week 10 of stage 2, confirmed. At ₹162 it trades +2.1% versus its 200-day average and sits at 47% of its 52-week range (₹124–₹204).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +9,474% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-07-17) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Avantel Ltd trades at 251.0× P/E, at the pricey end of its own range (93rd percentile). Its long-run median P/E is 58.0×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 251.0× is at the pricey end of its own range (93rd percentile), against a long-run median of 58.0× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −73.7% against a +26.7% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +45.7%/yr price move, ~−17.3%/yr came from earnings growth and ~+63.0 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Avantel Ltd reads as deteriorating on its fundamental arc. Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −3.2% latest against +58.1% at its 12-quarter best), ROCE slipping at 11.4%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −10.4% | +13.1% | +23.4% | +24.5% |
| Profit | −73.2% | −17.8% | +0.0% | +31.1% |
| EPS | −73.7% | −18.1% | −0.7% | +39.5% |
| Share price | +26.7% | +45.7% | +64.9% | +54.7% |
4-Factor Sector Score
35.7/100 — rank 19 of 24 in Aerospace & Defence - Equipments · 77% evidence confidence
Avantel Ltd scores 35.7 out of 100 against the 24 companies it is compared with in Aerospace & Defence - Equipments, ranking 19. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 10.1 + 9.2 + 8.7 + 7.7 = 35.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Avantel Ltd reported ₹70.4 Cr of revenue in the Jun 26 quarter, +35.7% year on year. That is the 2nd straight quarter of year-on-year growth. Over 10 years it has compounded at 24.5% a year. The last full year, FY26, came in at ₹223 Cr. The last four reported quarters add to ₹241 Cr.
FY26 revenue came in at ₹223 Cr (−10.4% on the year), capping 10 years at 24.5% compound. The latest quarter (Jun 26) printed ₹70.4 Cr, +35.7% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +2.5% growth against the decade's 24.5% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −3.2% over the last 4 quarters against +7.9%/yr over the last 8 — rolling over; TTM profit −67.2% vs −42.5%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Avantel Ltd's operating margin is 24.8% in the Jun 26 quarter, +4.6 percentage points against the same quarter a year ago. Across 15 fiscal years the operating margin has ranged 11.0% to 37.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 24.8%, +4.6 pp against the same quarter a year ago. Across 15 fiscal years the operating margin has ranged 11.0%–37.0%.
Why the margin moved: operating margin went +4.6 pp year on year while gross margin went +6.5 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Avantel Ltd earned ₹5.4 Cr of net profit in the Jun 26 quarter, +66.9% year on year. Full-year FY26 profit was ₹15.0 Cr. The 10-year compound rate is 31.1%. That is 7.7% of the quarter's revenue. The same quarter a year earlier earned ₹3.2 Cr.
Jun 26 profit was ₹5.4 Cr, +66.9% year on year. On the full year, FY26 printed ₹15.0 Cr (−73.2%), and the 10-year compound rate is 31.1%.
Why profit moved: revenue contributed +35.7% and the margin +4.6 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit −30.6% vs revenue +2.5%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 101% of Avantel Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹10.0 Cr of operating cash against ₹15.0 Cr of profit. After ₹87.0 Cr of capital spending, ₹−77.0 Cr was left as free cash.
FY26: operating cash of ₹10.0 Cr against reported profit of ₹15.0 Cr, leaving free cash of ₹−77.0 Cr after ₹87.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 101% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 101%: the cash cycle stretched 536 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 4.7× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Avantel Ltd's cash conversion cycle runs 627 days in FY26, up from 91 days in FY21. Capital spending ran ₹187 Cr over the last 3 years. At FY26 sales of ₹223 Cr each day of that cycle holds about ₹0.6 Cr, so roughly ₹383 Cr sits inside the business at any moment.
FY26: debtors at 117 days, inventory at 521 days — roughly 17.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 627 days, looser than FY21's 91.
The full loop: cash goes out to suppliers and production on day 0; stock waits 521 days to sell; customers pay about 117 days after that; and suppliers themselves are paid at 11 days — netting out to the 627-day cycle.
In money terms: at FY26 sales of ₹223 Cr, each day of the cycle holds about ₹0.6 Cr — so the 627-day loop keeps roughly ₹383 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹187 Cr over the last 3 fiscal years against ₹40.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹6.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Avantel Ltd earns a ROCE of 10% in FY26. That is up from a trough of 0% in FY14. Return on invested capital clears the cost of that capital by −6.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 6.7% net margin on 0.54× asset turns.
FY26 ROCE is 10%, recovered from a FY14 trough of 0% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 6.7% net margin × 0.54× asset turns × 1.21× balance-sheet leverage ≈ 4.4% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 5.4% − 12.0% = a −6.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Avantel Ltd carries total debt of ₹34.0 Cr against shareholder equity of ₹338 Cr as of Jun 26, a debt-to-equity of 0.10 — effectively unlevered. On the annual view that ratio went from 0.19 in FY22 to 0.10 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of ₹34.0 Cr against shareholder equity of ₹338 Cr — a debt-to-equity of 0.10. On the annual view, debt-to-equity went from 0.19 (FY22) to 0.10 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 3.0 points of Avantel Ltd over 8 quarters, the biggest move on the register. That takes promoters to 37.0% of the company. Foreign institutions moved +1.5 points over the same window, to 1.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −3.0 points over 8 quarters to 37.0%; Foreign institutions: +1.5 points over 8 quarters to 1.5%; Domestic institutions: +0.8 points over 8 quarters to 1.1%.
🚨 Why the register moved: promoters drove it (−3.0 points), absorbed on the other side by foreign institutions (+1.5 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Avantel Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Sigma Advanced System LtdSIGMAADV | 72.6/100Favorable setup93% evidence | LEADER | 24.0/35 Revenue 100% · PAT 100% · OPM change -12 pp 83% evidence | 16.6/25 ROCE 60.8% · OPM 17% 95% evidence | 12.0/20 P/E 42.6× · PEG 2.35 100% evidence | 20.0/20 RS sector 105.2% · RS bench 142.5% · 1Y 494.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 16.6 + 12 + 20 = 72.6 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Sika Interplant Systems LtdSIKA | 72.6/100Favorable setup90% evidence | TURNING | 28.4/35 Revenue 43% · PAT 38.1% · OPM change 7.9 pp 88% evidence | 21.9/25 ROCE 34.6% · OPM 25.2% 100% evidence | 12.9/20 P/E 67.4× · PEG 1.01 100% evidence | 9.4/20 RS sector -10.2% · RS bench 6% · 1Y -1.7%3 of 7 weeks ahead 70% evidence |
| Exact sum: 28.4 + 21.9 + 12.9 + 9.4 = 72.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Astra Microwave Products LtdASTRAMICRO | 70.5/100Favorable setup96% evidence | LEADER | 21.0/35 Revenue 10.6% · PAT 27% · OPM change 4 pp 88% evidence | 19.4/25 ROCE 20.2% · OPM 33% 100% evidence | 10.8/20 P/E 91.6× · PEG 1.19 100% evidence | 19.3/20 RS sector 30.4% · RS bench 61.4% · 1Y 90.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 19.4 + 10.8 + 19.3 = 70.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Paras Defence and Space Technologies LtdPARAS | 66.4/100Favorable setup78% evidence | LEADER | 21.8/35 Revenue 30.4% · PAT 43.5% · OPM change -1 pp 83% evidence | 16.8/25 ROCE 16.9% · OPM 25% 76% evidence | 9.2/20 P/E 118× · PEG — 50% evidence | 18.6/20 RS sector 27.1% · RS bench 57.1% · 1Y 60.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 16.8 + 9.2 + 18.6 = 66.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5MTAR Technologies LtdMTARTECH | 63.2/100Mixed-positive evidence90% evidence | FADING | 30.7/35 Revenue 53.5% · PAT 100% · OPM change 6 pp 100% evidence | 13.9/25 ROCE 15.1% · OPM 24% 100% evidence | 6.3/20 P/E 129× · PEG — 50% evidence | 12.3/20 RS sector 21.9% · RS bench 44.7% · 1Y 280.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 30.7 + 13.9 + 6.3 + 12.3 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Apollo Micro Systems LtdAPOLLO | 59.9/100Mixed-positive evidence96% evidence | LEADER | 21.9/35 Revenue 60.9% · PAT 92.9% · OPM change 1 pp 88% evidence | 14.2/25 ROCE 14.5% · OPM 23% 100% evidence | 7.1/20 P/E 128× · PEG 1.6 100% evidence | 16.7/20 RS sector 6.5% · RS bench 32% · 1Y 126.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 14.2 + 7.1 + 16.7 = 59.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Vinyas Innovative Technologies LtdVINYAS | 59.3/100Thin evidence · provisional57% evidence | TURNING | 21.7/35 Revenue 65% · PAT 100% · OPM change 3 pp 48% evidence | 18.5/25 ROCE 21.4% · OPM 13% 95% evidence | 10.9/20 P/E 51.1× · PEG — 15% evidence | 8.2/20 RS sector -17.5% · RS bench 6% · 1Y -6.9%10 of 11 weeks ahead 70% evidence |
| Exact sum: 21.7 + 18.5 + 10.9 + 8.2 = 59.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Data Patterns (India) LtdDATAPATTNS | 58.1/100Mixed-positive evidence100% evidence | FADING | 21.5/35 Revenue 33.9% · PAT 24.2% · OPM change -5 pp 100% evidence | 18.6/25 ROCE 21.9% · OPM 27% 100% evidence | 5.0/20 P/E 88.7× · PEG 3.94 100% evidence | 13.0/20 RS sector 5% · RS bench 30.1% · 1Y 59.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 18.6 + 5 + 13 = 58.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 9Azad Engineering LtdAZAD | 57.4/100Mixed-positive evidence89% evidence | FADING | 24.5/35 Revenue 32.2% · PAT 54% · OPM change 2 pp 88% evidence | 12.9/25 ROCE 11.9% · OPM 38% 100% evidence | 8.0/20 P/E 111× · PEG 2.29 65% evidence | 12.0/20 RS sector 1.6% · RS bench 27% · 1Y 47.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 12.9 + 8 + 12 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Ideaforge Technology LtdIDEAFORGE | 57.1/100Mixed-positive evidence68% evidence | LEADER | 24.6/35 Revenue 41% · PAT 71.4% · OPM change 152 pp 65% evidence | 4.6/25 ROCE -2.8% · OPM 44% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 17.9/20 RS sector 25.6% · RS bench 53.6% · 1Y 85.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 4.6 + 10 + 17.9 = 57.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Hindustan Aeronautics LtdHAL | 56.2/100Mixed-positive evidence96% evidence | BREAKING OUT | 11.0/35 Revenue 6.8% · PAT 9% · OPM change -3 pp 88% evidence | 21.1/25 ROCE 32% · OPM 36% 100% evidence | 15.2/20 P/E 34.1× · PEG 1.18 100% evidence | 8.9/20 RS sector -18.6% · RS bench 4% · 1Y 2.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 11 + 21.1 + 15.2 + 8.9 = 56.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Rossell Techsys LtdROSSTECH | 54.1/100Mixed-positive evidence83% evidence | FADING | 29.0/35 Revenue 82.9% · PAT 68.8% · OPM change 1.8 pp 100% evidence | 7.4/25 ROCE 11.5% · OPM 14.4% 100% evidence | 9.0/20 P/E 136× · PEG — 15% evidence | 8.7/20 RS sector -3.2% · RS bench 20.7% · 1Y 64.3%9 of 12 weeks ahead 100% evidence |
| Exact sum: 29 + 7.4 + 9 + 8.7 = 54.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Jaykay Enterprises LtdJAYKAY | 49.0/100Mixed-negative evidence62% evidence | ASLEEP | 25.8/35 Revenue 100% · PAT 100% · OPM change 34 pp 62% evidence | 6.8/25 ROCE 8.2% · OPM -10% 95% evidence | 11.5/20 P/E 32.6× · PEG — 15% evidence | 4.9/20 RS sector -20.9% · RS bench -6.2% · 1Y 20.6%6 of 10 weeks ahead 70% evidence |
| Exact sum: 25.8 + 6.8 + 11.5 + 4.9 = 49 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -20.9% and the one-year return is 20.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 14Mishra Dhatu Nigam LtdMIDHANI | 45.7/100Mixed-negative evidence96% evidence | FADING | 16.3/35 Revenue 12.6% · PAT 18.9% · OPM change -2 pp 88% evidence | 13.7/25 ROCE 11.3% · OPM 21% 100% evidence | 7.4/20 P/E 56.4× · PEG 5.62 100% evidence | 8.3/20 RS sector -16.9% · RS bench 5.1% · 1Y -2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 13.7 + 7.4 + 8.3 = 45.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Dynamatic Technologies LtdDYNAMATECH | 43.8/100Mixed-negative evidence89% evidence | FADING | 16.2/35 Revenue 15.5% · PAT -23.3% · OPM change 1 pp 88% evidence | 10.2/25 ROCE 10% · OPM 11% 100% evidence | 10.3/20 P/E 140× · PEG 1.42 65% evidence | 7.1/20 RS sector -12.3% · RS bench 10.4% · 1Y 47.5%4 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 10.2 + 10.3 + 7.1 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Zen Technologies LtdZENTEC | 41.9/100Mixed-negative evidence69% evidence | ASLEEP | 5.0/35 Revenue -23.4% · PAT -27.8% · OPM change -14 pp 95% evidence | 16.6/25 ROCE 16.2% · OPM 27% 76% evidence | 10.5/20 P/E 80.7× · PEG — 15% evidence | 9.8/20 RS sector -6.5% · RS bench 6.5% · 1Y -8.7%8 of 10 weeks ahead 70% evidence |
| Exact sum: 5 + 16.6 + 10.5 + 9.8 = 41.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Bharat Electronics LtdBEL | 41.7/100Mixed-negative evidence100% evidence | ASLEEP | 14.0/35 Revenue 19.8% · PAT 11.8% · OPM change -3 pp 100% evidence | 18.6/25 ROCE 36.5% · OPM 25% 100% evidence | 7.3/20 P/E 46.1× · PEG 3.54 100% evidence | 1.8/20 RS sector -28% · RS bench -8% · 1Y -1.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14 + 18.6 + 7.3 + 1.8 = 41.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Aequs LtdAEQUS | 36.4/100Thin evidence · provisional51% evidence | BREAKING OUT | 15.1/35 Revenue 44.3% · PAT — · OPM change -7.3 pp 74% evidence | 1.3/25 ROCE 1.6% · OPM 3.7% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 15.1 + 1.3 + 10 + 10 = 36.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Avantel Ltdthis pageAVANTEL | 35.7/100Mixed-negative evidence77% evidence | TURNING | 10.1/35 Revenue -3.2% · PAT -67.2% · OPM change 4.6 pp 100% evidence | 9.2/25 ROCE 9.6% · OPM 24.8% 100% evidence | 8.7/20 P/E 251× · PEG — 15% evidence | 7.7/20 RS sector -11.9% · RS bench 0.1% · 1Y 19%8 of 11 weeks ahead 70% evidence |
| Exact sum: 10.1 + 9.2 + 8.7 + 7.7 = 35.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20AXISCADES Technologies LtdAXISCADES | 35.4/100Mixed-negative evidence96% evidence | ASLEEP | 15.4/35 Revenue 12.4% · PAT -4.3% · OPM change -1.7 pp 88% evidence | 12.3/25 ROCE 15.3% · OPM 12.3% 100% evidence | 4.9/20 P/E 83.6× · PEG 3.04 100% evidence | 2.8/20 RS sector -21.3% · RS bench -1.3% · 1Y 13.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 15.4 + 12.3 + 4.9 + 2.8 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21NIBE LtdNIBE | 32.4/100Adverse evidence65% evidence | TURNING | 9.6/35 Revenue -6.7% · PAT -80% · OPM change 3 pp 83% evidence | 7.6/25 ROCE 4.8% · OPM 20% 76% evidence | 8.5/20 P/E 380× · PEG — 15% evidence | 6.7/20 RS sector -29.8% · RS bench 11.1% · 1Y -17%11 of 11 weeks ahead 70% evidence |
| Exact sum: 9.6 + 7.6 + 8.5 + 6.7 = 32.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Bharat Dynamics LtdBDL | 29.4/100Adverse evidence83% evidence | ASLEEP | 7.6/35 Revenue -27% · PAT -23.6% · OPM change -5 pp 88% evidence | 12.9/25 ROCE 13.8% · OPM 12% 100% evidence | 5.0/20 P/E 109× · PEG 4.44 65% evidence | 3.9/20 RS sector -22.4% · RS bench -11.8% · 1Y -24.4%2 of 10 weeks ahead 70% evidence |
| Exact sum: 7.6 + 12.9 + 5 + 3.9 = 29.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23BEML LtdBEML | 26.3/100Adverse evidence90% evidence | ASLEEP | 6.5/35 Revenue 8.1% · PAT -51.5% · OPM change -11 pp 88% evidence | 5.3/25 ROCE 7.7% · OPM 15% 100% evidence | 9.5/20 P/E 103× · PEG 1.18 100% evidence | 5.0/20 RS sector -19.9% · RS bench -6.2% · 1Y -15.6%5 of 10 weeks ahead 70% evidence |
| Exact sum: 6.5 + 5.3 + 9.5 + 5 = 26.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24DCX Systems LtdDCXINDIA | 25.1/100Adverse evidence67% evidence | ASLEEP | 8.2/35 Revenue -31.4% · PAT -80% · OPM change -2 pp 83% evidence | 3.4/25 ROCE 0.9% · OPM -0.2% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.5/20 RS sector -27% · RS bench -12.4% · 1Y -32%5 of 10 weeks ahead 70% evidence |
| Exact sum: 8.2 + 3.4 + 10 + 3.5 = 25.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Avantel Ltd's share price today?
Avantel Ltd trades at ₹162, +26.7% over the past year. The company is valued at ₹4,302 Cr. The stock sits at 47% of its 52-week range of ₹124–₹204, +2.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 10 weeks in. — as of 31 July 2026.
What were Avantel Ltd's latest quarterly results?
Avantel Ltd reported revenue of ₹70.4 Cr and net profit of ₹5.4 Cr for the Jun 26 quarter. Revenue rose 35.7% and profit rose 66.9% year on year. Earnings per share were ₹0.20. The operating margin was 24.8%, 4.6 pp higher than a year earlier. — as of 31 July 2026.
What is Avantel Ltd's revenue?
Avantel Ltd reported revenue of ₹70.4 Cr in the Jun 26 quarter, +35.7% year on year. For the full FY26 fiscal year, revenue was ₹223 Cr (−10.4%). Over the last 10 years revenue compounded at 24.5% a year. — as of 31 July 2026.
What is Avantel Ltd's profit?
Avantel Ltd earned ₹5.4 Cr of net profit in the Jun 26 quarter, +66.9% year on year. Full-year FY26 profit was ₹15.0 Cr. The operating margin ran 24.8% in the latest quarter. — as of 31 July 2026.
What is Avantel Ltd's market cap?
Avantel Ltd's market capitalisation is ₹4,302 Cr at a share price of ₹162. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Avantel Ltd's P/E ratio?
Avantel Ltd trades at a P/E of 251.0×, at the 93rd percentile of its own 10-year range, against a long-run median of 58.0×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Avantel Ltd pay a dividend?
Yes — Avantel Ltd's dividend payout was 35% of profit in FY26, and it recorded a payout in 13 of its last 15 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Avantel Ltd overvalued?
On its own history, Avantel Ltd looks expensive against its own history: its P/E of 251.0× sits at the 93rd percentile of its 10-year range (long-run median 58.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Avantel Ltd growing?
Yes — Avantel Ltd is growing: latest-quarter revenue +35.7% year on year, profit +66.9%, and the margin +4.6 pp at 24.8%. The 10-year compound rates are 24.5% (revenue) and 31.1% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Avantel Ltd performing?
Avantel Ltd is in a confirmed uptrend, 10 weeks in. Its latest quarter's revenue rose 35.7% and profit rose 66.9% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Avantel Ltd in?
Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −3.2% latest against +58.1% at its 12-quarter best), ROCE slipping at 11.4%. The read comes from the last 12 quarters of growth (revenue growth −3.2% latest, profit growth −67.2% latest, eps growth −67.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Avantel Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 10 of stage 2), trading +2.1% versus its 200-day average and at 47% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Avantel Ltd beating the market?
Not lately — on a trailing-13-week view Avantel Ltd is currently behind the NIFTY 500 (2 weeks and counting; last ahead the week of 2026-07-17), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +9,474% against the NIFTY 500's +276% — ahead of the index over the full window. — as of 31 July 2026.
Will Avantel Ltd's share price go up?
This page publishes no price forecast for Avantel Ltd. What it measures instead: the share price is ₹162, the price is in a confirmed uptrend 10 weeks in. Its P/E of 251.0× sits at the 93rd percentile of its own 10-year range. — as of 31 July 2026.
Who owns Avantel Ltd?
Promoters hold 37.0% of Avantel Ltd, foreign institutions 1.5%, domestic institutions 1.1% and the public 60.3% (latest quarter). The biggest move on the register over the last two years: Promoters cut 3.0 points over 8 quarters. — as of 31 July 2026.
Does Avantel Ltd have too much debt?
No — Avantel Ltd's debt-to-equity is 0.10, and operating profit covers the interest bill 8×. FY26 borrowings were ₹34.0 Cr against equity of ₹338 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Avantel Ltd's capex?
Avantel Ltd spent ₹187 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹87.0 Cr, with ₹6.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Avantel Ltd's cash flow?
Avantel Ltd generated ₹10.0 Cr of operating cash flow in FY26 and ₹−77.0 Cr of free cash flow after ₹87.0 Cr of capital spending. Reported profit that year was ₹15.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Avantel Ltd's profit real cash?
Yes — over the last 3 fiscal years, 101% of Avantel Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹10.0 Cr against reported profit of ₹15.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Avantel Ltd in its business cycle?
Avantel Ltd's FY26 operating margin was 22.0%, against a 15-year band of 11.0%–37.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 24.8%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Avantel Ltd story?
The sharpest disagreement: the price moved +26.7% in a year while annual EPS moved −73.7% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Avantel Ltd a stock worth studying right now?
This is not investment advice. The machine read: Avantel Ltd's price has outrun its earnings. +26.7% in a year against EPS −73.7% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.